title: Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.
abstract: A 29-year-old pregnant woman diagnosed with acute lymphocytic leukemia maintained remission with daily cyclophosphamide and intermittent prednisone treatment. She delivered a male twin with multiple congenital abnormalities who was diagnosed with papillary thyroid cancer at 11 years of age and stage III neuroblastoma at 14 years of age. The female twin was unaffected and has exhibited normal development to date. First trimester exposure to cyclophosphamide has been associated with major malformations. Metabolites of cyclophosphamide have been demonstrated to be teratogens and carcinogens in animals. Differences in placental or fetal hepatic cytochrome P-450 may account for the variability in response between the twins. In addition, disparity between the twins may be the result of differences in metabolite inactivating enzymes present either in fetal liver or placenta. The risk of second malignancies caused by alkylating agents such as cyclophosphamide has been well documented in adults and children but to the best of our knowledge this is the first description of transplacental second cancer.
authors.affiliation: Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Zemlickis
authors.forename: M
authors.initials: M
authors.lastname: Lishner
authors.forename: R
authors.initials: R
authors.lastname: Erlich
authors.forename: G
authors.initials: G
authors.lastname: Koren
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000015:Abnormalities, Multiple / Q000139:chemically induced*; D000310:Adrenal Gland Neoplasms / Q000139:chemically induced*; D000328:Adult; D000630:Aminopterin / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D004200:Diseases in Twins; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D015122:Mercaptopurine / Q000008:administration & dosage; D009447:Neuroblastoma / Q000139:chemically induced*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy; D011297:Prenatal Exposure Delayed Effects; D013964:Thyroid Neoplasms / Q000139:chemically induced*; D013997:Time Factors; D014429:Twins, Dizygotic; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D000630:Aminopterin; D011241:Prednisone